GLMD vs. PBLA, DRMA, GRI, CMRA, INM, QLGN, LSDI, NBSE, BPTH, and CMND
Should you be buying Galmed Pharmaceuticals stock or one of its competitors? The main competitors of Galmed Pharmaceuticals include Panbela Therapeutics (PBLA), Dermata Therapeutics (DRMA), GRI Bio (GRI), Comera Life Sciences (CMRA), InMed Pharmaceuticals (INM), Qualigen Therapeutics (QLGN), Lucy Scientific Discovery (LSDI), NeuBase Therapeutics (NBSE), Bio-Path (BPTH), and Clearmind Medicine (CMND). These companies are all part of the "pharmaceutical preparations" industry.
Galmed Pharmaceuticals (NASDAQ:GLMD) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Galmed Pharmaceuticals received 424 more outperform votes than Panbela Therapeutics when rated by MarketBeat users. However, 69.23% of users gave Panbela Therapeutics an outperform vote while only 65.77% of users gave Galmed Pharmaceuticals an outperform vote.
Galmed Pharmaceuticals' return on equity of -53.29% beat Panbela Therapeutics' return on equity.
In the previous week, Galmed Pharmaceuticals and Galmed Pharmaceuticals both had 2 articles in the media. Panbela Therapeutics' average media sentiment score of 0.00 beat Galmed Pharmaceuticals' score of -0.33 indicating that Panbela Therapeutics is being referred to more favorably in the news media.
Galmed Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500.
76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.4% of Panbela Therapeutics shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
Panbela Therapeutics has a consensus target price of $500.00, indicating a potential upside of 124,900.00%. Given Panbela Therapeutics' higher possible upside, analysts plainly believe Panbela Therapeutics is more favorable than Galmed Pharmaceuticals.
Summary
Galmed Pharmaceuticals beats Panbela Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Galmed Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galmed Pharmaceuticals Competitors List
Related Companies and Tools
